CAD106
Novartis presents positive results from two phase 3 trials for relapsing MS
Remibrutinib reduced relapse rates and improved disease progression rates
Galimedix establishes Alzheimer’s Disease Scientific Advisory Board
The Board will advise Galimedix on scientific and clinical strategy
Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica
If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica
Novartis announces trial results for remibrutinib in relapsing multiple sclerosis
MS affects nearly three million people worldwide and has three main types
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
Alzheimer’s groups call for urgent global focus on women’s brain health
New op-ed published by leaders from the Women’s Alzheimer’s Movement at Cleveland Clinic, Alzheimer’s Research UK and the Alzheimer’s Association
Novartis to acquire Myricx Bio in deal worth $1.5bn
Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates
Novartis breaks ground on US radioligand therapy site
The construction is part of the company’s investment in US research and manufacturing
AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment
The agreement covers the development of new lead tau morphomer candidates
Novartis to acquire Excellergy in deal worth up to $2bn
Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases
Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term
The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark
Scotland becomes first part of UK to screen all newborn babies for SMA
The screening is part of a two-year evaluation funded by the Scottish government and Novartis